Cepheid, a California-based molecular diagnostics company, and the Foundation for Innovative New Diagnostics (FIND) announced a new collaboration to accelerate the development of a rapid HIV viral load test. This viral load test will run on the platform of Cepheid’s GeneXpert, the ground-breaking rapid test to diagnose drug-susceptible and drug-resistant tuberculosis. Given the high rates of TB/HIV co-infection, especially in southern Africa, a diagnostic with both these capabilities could be incredibly beneficial in diagnosing and managing these two deadly infectious diseases. To read the full press announcement, click here.
Amid unprecedented challenges to routine healthcare access, trial results mark a first for a critically needed HIV prevention measure An investigational drug administered by injection every […]
In the six weeks before South Africa responded its first diagnoses of COVID-19 with the start of physical distancing measures, more than 47,000 people on average […]
What we have learned from HIV can guide responses to COVID-19 that are innovative, effective and inclusive, and can help end the pandemic faster The following […]
The following is a guest post by Kenneth G. Castro, MD, FIDSA Since its formation in 1948, WHO has relied heavily on the U.S. for collaborations […]